WO2009076629A2 - Compositions et procédés pour le traitement du cancer - Google Patents

Compositions et procédés pour le traitement du cancer Download PDF

Info

Publication number
WO2009076629A2
WO2009076629A2 PCT/US2008/086669 US2008086669W WO2009076629A2 WO 2009076629 A2 WO2009076629 A2 WO 2009076629A2 US 2008086669 W US2008086669 W US 2008086669W WO 2009076629 A2 WO2009076629 A2 WO 2009076629A2
Authority
WO
WIPO (PCT)
Prior art keywords
atdc
cells
cancer
catenin
expression
Prior art date
Application number
PCT/US2008/086669
Other languages
English (en)
Inventor
Diane Simeone
Mats Ljungman
Liang Xu
Lidong Wang
Original Assignee
The Regents Of The University Of Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by The Regents Of The University Of Michigan filed Critical The Regents Of The University Of Michigan
Publication of WO2009076629A2 publication Critical patent/WO2009076629A2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088—Compounds having three or more nucleosides or nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
PCT/US2008/086669 2007-12-12 2008-12-12 Compositions et procédés pour le traitement du cancer WO2009076629A2 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US1310907P 2007-12-12 2007-12-12
US61/013,109 2007-12-12

Publications (1)

Publication Number Publication Date
WO2009076629A2 true WO2009076629A2 (fr) 2009-06-18

Family

ID=40756139

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/086669 WO2009076629A2 (fr) 2007-12-12 2008-12-12 Compositions et procédés pour le traitement du cancer

Country Status (2)

Country Link
US (1) US8088749B2 (fr)
WO (1) WO2009076629A2 (fr)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011128886A1 (fr) * 2010-04-12 2011-10-20 Ramot At Tel Aviv University Ltd. Micro-arn pour le diagnostic, le pronostic et la thérapie du cancer
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
CN104513852A (zh) * 2014-06-13 2015-04-15 南通大学附属医院 miRNAs在胃癌干细胞中表达谱的分析方法
CN108196059A (zh) * 2017-12-01 2018-06-22 南京医科大学 三联组氨酸核苷结合蛋白的应用

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011088309A1 (fr) 2010-01-14 2011-07-21 Regulus Therapeutics Inc. Compositions de microarn et procédés
WO2012167099A1 (fr) * 2011-06-01 2012-12-06 Baylor College Of Medicine Biomarqueurs et thérapie contre le cancer
WO2013116589A1 (fr) * 2012-02-02 2013-08-08 St. Jude Children's Research Hospital Procédés pour le diagnostic et le traitement de troubles d'apprentissage ou mentaux
US20150126581A1 (en) * 2012-03-08 2015-05-07 The University Of Western Australia MicroRNAs and Uses Thereof
EP2872161B1 (fr) 2012-06-26 2020-12-16 Del Mar Pharmaceuticals Dianhydrogalactitol pour utilisation dans le traitement de malignités résistantes à un inhibiteur de tyrosine kinase chez des patients ayant des polymorphismes génétiques ou des dérégulations ou des mutations d'ahi1
EP2983674A4 (fr) 2013-04-08 2017-05-10 Dennis M. Brown Bénéfice thérapeutique de composés chimiques administrés de façon sous-optimale
US10363324B2 (en) * 2013-11-04 2019-07-30 The South African Nuclear Energy Corporation Limited Pharmaceutical composition
US11384380B2 (en) 2016-03-16 2022-07-12 Yale University Compositions and methods for detecting N6-methyladenine in the mammalian genome

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2416954A1 (fr) * 1978-02-08 1979-09-07 Pechiney Ugine Kuhlmann Traitement non polluant d'effluents uraniferes provenant d'une attaque alcaline d'un minerai d'uranium contenant du soufre
DE2818886C2 (de) * 1978-04-28 1986-03-27 Kraftwerk Union AG, 4330 Mülheim Kernumfassung und Verfahren zu ihrer Herstellung
DE3128855A1 (de) * 1981-07-22 1983-02-10 Metallgesellschaft Ag, 6000 Frankfurt Verfahren zur ausfaellung von oxidischem uran aus sodaalkalischen loesungen durch reduktion mit metallischem eisen
DE3144974C2 (de) * 1981-11-12 1986-01-09 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur Abtrennung von Aktinoidenionen aus wäßrigen, basischen, carbonathaltigen Lösungen
US4410497A (en) * 1982-01-26 1983-10-18 Mobil Oil Corporation Separation of uranium from carbonate containing solutions thereof by direct precipitation
FR2553750A1 (fr) * 1983-10-20 1985-04-26 Pechiney Uranium Procede de separation selective d'uranium, zirconium et/ou hafnium et/ou molybdene a partir d'une solution aqueuse carbonatee les contenant
DE3428877A1 (de) * 1984-08-04 1986-02-13 Kernforschungszentrum Karlsruhe Gmbh, 7500 Karlsruhe Verfahren zur trennung von grossen mengen uran von geringen mengen von radioaktiven spaltprodukten, die in waessrigen basischen, karbonathaltigen loesungen vorliegen
US5384104A (en) * 1992-11-16 1995-01-24 Westinghouse Electric Corporation Uranium carbonate extraction process
US5640668A (en) * 1996-03-20 1997-06-17 Krot; Nikolai N. Removal of dissolved actinides from alkaline solutions by the method of appearing reagents
US6749863B1 (en) * 1997-11-19 2004-06-15 Georgetown University Targeted liposome gene delivery
US6471922B1 (en) * 1999-03-01 2002-10-29 The Regents Of The University Of California Actinide removal from spent salts

Cited By (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8835506B2 (en) 2008-06-05 2014-09-16 Stc.Unm Methods and related compositions for the treatment of cancer
US9326974B2 (en) 2008-06-05 2016-05-03 Stc.Unm Methods and related compositions for the treatment of cancer
WO2011128886A1 (fr) * 2010-04-12 2011-10-20 Ramot At Tel Aviv University Ltd. Micro-arn pour le diagnostic, le pronostic et la thérapie du cancer
CN104513852A (zh) * 2014-06-13 2015-04-15 南通大学附属医院 miRNAs在胃癌干细胞中表达谱的分析方法
CN104513852B (zh) * 2014-06-13 2016-08-24 南通大学附属医院 miRNAs在胃癌干细胞中表达谱的分析方法
CN108196059A (zh) * 2017-12-01 2018-06-22 南京医科大学 三联组氨酸核苷结合蛋白的应用
CN108196059B (zh) * 2017-12-01 2018-11-09 南京医科大学 三联组氨酸核苷结合蛋白的应用

Also Published As

Publication number Publication date
US20090192112A1 (en) 2009-07-30
US8088749B2 (en) 2012-01-03

Similar Documents

Publication Publication Date Title
US8088749B2 (en) Compositions and methods for treating cancer
US20210355495A1 (en) Methods to eliminate cancer stem cells by targeting cd47
Lamers et al. Knockdown of survivin (BIRC5) causes apoptosis in neuroblastoma via mitotic catastrophe
ES2627059T3 (es) Regiones ultraconservadas que codifican ARNnc
AU2014348291A9 (en) Compositions and methods of using transposons
ES2727334T3 (es) Métodos y ensayos basados en microARN para el osteosarcoma
US10337012B2 (en) Method and composition for the treatment, prevention, and diagnosis of cancer containing or derived from cancer stem cells
JP6612842B2 (ja) がんの脳転移の診断、予防及び治療方法、並びに血液脳関門を通過させるための医薬送達システム
US20220282250A1 (en) Long non-coding rna in cancer
Zhang et al. The LncRNA CASC11 promotes colorectal cancer cell proliferation and migration by adsorbing miR-646 and miR-381-3p to upregulate their target RAB11FIP2
Cheng et al. Circ_0007624 suppresses the development of esophageal squamous cell carcinoma via targeting miR-224-5p/CPEB3 to inactivate the EGFR/PI3K/AKT signaling
ES2828510T3 (es) Agente terapéutico para tratar un cáncer en el que NRF2 está estabilizado
CA2936254A1 (fr) Traitement de tumeurs exprimant la p53 mutante
Qin et al. LINC01207 promotes prostate cancer progression by sponging miR‑1182 to upregulate AKT3
KR102270926B1 (ko) Banf1, plod3 또는 sf3b4의 억제제를 유효성분으로 포함하는 간암의 예방 및 치료용 조성물
Lin et al. P4HA2, a prognostic factor, promotes glioma proliferation, invasion, migration and EMT through collagen regulation and PI3K/AKT pathway
US10905708B2 (en) MicroRNA-based methods and assays for osteocarcinoma
US10233463B2 (en) Neurotensin-induced tumor formation is regulated by micro RNA 133A-aftiphilin-dependent receptor recycling
Zhao et al. LncRNA H19 facilitates polarization of M1 phenotype macrophages via miR-145-5p/PAI-1 axis in mediating systemic lupus erythematosus
US20150050360A1 (en) Pharmaceutical compositions for treating cancer
US20200325539A1 (en) Cancer biomarkers and methods of use
WO2023211366A2 (fr) Méthode de pronostic et de traitement d'un gliome
KR20230077936A (ko) 구강암의 시스플라틴 내성 예측용 바이오마커 및 이의 용도
WO2024037910A1 (fr) Inhibiteurs de syk destinés à être utilisés dans le traitement du cancer
WO2014095916A1 (fr) Ninjurine-1 comme cible thérapeutique pour une tumeur du cerveau

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08859947

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08859947

Country of ref document: EP

Kind code of ref document: A2